<DOC>
	<DOCNO>NCT01138475</DOCNO>
	<brief_summary>Evaluate efficacy paricalcitol , cholecalciferol , placebo reduction parathyroid hormone patient Roux-en-Y gastric bypass surgery ( RYGB ) . Assess change , , measure self-assessed well-being attributable paricalcitol RYGB . Evaluate rate hypercalcemia , kidney stone , gastrointestinal side effect , organ system adverse effect paricalcitol , cholecalciferol , placebo patient RYGB</brief_summary>
	<brief_title>Trial Of Paricalcitol Cholecalciferol ( Vitamin D3 ) Treatment Of Secondary Hyperparathyroidism Patients After ROUX-EN-Y Gastric Bypass Surgery</brief_title>
	<detailed_description />
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>1 . Subject voluntarily sign date informed consent form , approve Institutional Review Board ( IRB ) , nature study explain subject opportunity ask question . The informed consent must sign studyspecific procedure perform . 2 . Must post bariatric ( &gt; 6 week â‰¤ 5 year ) RouenY gastric bypass surgical patient . 3 . Male female subject &gt; 18 year . 4 . For entry Treatment Period subject must satisfy follow criterion base exist laboratory value previously draw clinical ground : Serum calcium level 8.010.5 mg/dL Phosphorous level &lt; 5.2 mg/dL ( 1.68 mmol/L ) Serum albumin &gt; 3.0 g/dL ( 30 g/L ) . 5 . For entry Treatment Period subject must satisfy follow criterion base screen laboratory ( Beaumont Reference Laboratories , screen laboratory value blind ) : iPTH &gt; 69 pg/ml Negative serum pregnancy test female subject childbearing potential . 6 . In opinion investigator , subject must receive optimal medical management co morbidity include limited HTN , DM , CVD , liver disease , lung disease . 7 . If female , subject breast feeding pregnant ( verified negative pregnancy test prior Treatment Period ) ; childbearing potential , defined postmenopausal least one year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) ; childbearing potential practice one follow method birth control : Doublebarrier method ( two follow : condom , contraceptive sponge , diaphragm , vaginal ring spermicidal jelly cream , intrauterine device [ IUD ] ) Hormonal contraceptive ( oral , parenteral , transdermal ) least three month prior study drug administration Maintains monogamous relationship vasectomize partner Total abstinence sexual intercourse study ( minimum one complete menstrual cycle prior study start ) . Subject previously active vitamin D therapy ( calcitriol , paricalcitol , doxercalciferol , alfacalcidol ) within 30day washout period prior Treatment Period dose great 1200 IU vitamin D3 equivalent . 2 . Subject history allergic reaction significant sensitivity paricalcitol drug similar study drug ( i.e. , vitamin D vitamin D related compound ) . 3 . Pregnant ( confirm screen pregnancy test ) lactating female . 4 . Subject expect initiate renal replacement therapy within one year . 5 . Known history hypercalcemia ( &gt; 10.5 mg/dl ) , hyperphosphatemia ( &gt; 6 mg/dl ) primary hyperparathyroidism , history endstage renal disease require renal replacement therapy . 6 . Full remission malignancy le one year ( except completely excise nonMelanoma skin cancer e.g. , basal squamous carcinoma ) history bone metastasis . 7 . Subject comorbid condition ( e.g. , advanced malignancy , advance liver disease ) life expectancy le 1 year . 8 . Subject receive investigational drug within 30 day prior study drug administration currently enrol another clinical trial . 9 . Subject history active kidney stone within 2 year prior Screening Period . 10 . Subject poorly control hypertension ( systolic blood pressure &gt; 180 mmHg and/or diastolic blood pressure &gt; 110 mmHg Screening Visit ( confirm repeat ) . 11 . Subject history renal artery stenosis , primary aldosteronism pheochromocytoma , 12 . Subject take calcitonin , bisphosphonates , cinacalcet , glucocorticoid ( except topical inhaled glucocorticoid ) , drug may affect calcium bone metabolism , aluminum , calcium noncalcium contain phosphate binder female subject stable ( dose product three month ) estrogen and/or progestin therapy . 13 . Subject currently receive immunosuppressant therapy and/or high dos ( nonmaintenance therapy ) glucocorticoid ( &gt; 5 mg/day prednisone equivalent ) . 14 . Subject acute renal failure within 12 week Screening Phase define acute rise serum Cr ( least 0.5 mg/dL 44 micromoles/L ) 4 g/dL ( 350 micromoles/L ) . 15 . Subject know HIV positive . 16 . Use known inhibitor ( i.e. , ketoconazole ) inducer ( i.e. , carbamazepine ) cytochrome P450 3 A ( CYP3 A ) within two week prior study drug administration . 17 . For reason , subject consider Investigator unsuitable candidate receive paricalcitol capsule put risk study procedure . 18 . Subject history drug alcohol abuse within six month prior screen . 19 . Subject liver kidney transplant . 20 . Stage V CKD subject renal replacement therapy explicitly exclude . 21 . Subject CVA within last 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>PTH</keyword>
	<keyword>Gastric bypass surgery</keyword>
	<keyword>vitamin D</keyword>
	<keyword>paricalcitol</keyword>
</DOC>